Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.95 -0.7%	$2.64	$0.87 ▼ $4.08	$410.70M	1.48	713,431 shs	815,258 shs
CNTB Connect Biopharma	$2.00 -1.0%	$1.25	$0.51 ▼ $2.86	$112.23M	-0.1	273,265 shs	240,596 shs
ERAS Erasca	$1.39 -1.8%	$1.46	$1.01 ▼ $3.31	$400.85M	1.05	812,222 shs	804,375 shs
RGNX REGENXBIO	$8.19 -3.8%	$8.88	$5.03 ▼ $13.48	$426.86M	1.11	559,914 shs	539,624 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	-0.67%	-7.23%	+12.60%	+56.08%	+186.41%
CNTB Connect Biopharma	-0.99%	-9.91%	+85.19%	+142.39%	+68.07%
ERAS Erasca	-1.77%	-20.11%	-4.14%	-12.03%	-55.87%
RGNX REGENXBIO	-3.76%	-8.59%	-4.99%	-21.25%	-42.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	2.3779 of 5 stars	3.6	1.0	0.0	1.1	5.0	0.0
CNTB Connect Biopharma	2.8446 of 5 stars	3.8	3.0	0.0	2.7	2.5	0.0
ERAS Erasca	2.0736 of 5 stars	3.5	0.0	0.0	1.2	2.5	1.3
RGNX REGENXBIO	4.1235 of 5 stars	3.4	1.0	4.6	2.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.10	Buy	$12.67	329.38% Upside
CNTB Connect Biopharma	3.50	Strong Buy	$7.00	250.00% Upside
ERAS Erasca	3.00	Buy	$4.57	228.88% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	286.14% Upside

Current Analyst Ratings Breakdown

Latest CNTB, RGNX, ERAS, and CMPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	CNTB Connect Biopharma	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
5/14/2025	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$3.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	479.92	N/A	N/A	$0.91 per share	3.24
CNTB Connect Biopharma	$26.03M	4.27	N/A	N/A	$1.67 per share	1.20
ERAS Erasca	N/A	N/A	N/A	N/A	$1.50 per share	N/A
RGNX REGENXBIO	$83.33M	4.93	N/A	N/A	$5.24 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
ERAS Erasca	-$161.65M	-$0.62	N/A	N/A	N/A	N/A	-36.56%	-31.08%	8/11/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.11	N/A	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)

Latest CNTB, RGNX, ERAS, and CMPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ERAS Erasca	-$0.12	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	RGNX REGENXBIO	-$1.13	N/A	N/A	N/A	$40.87 million	N/A
5/15/2025	Q1 2025	CNTB Connect Biopharma	-$0.26	-$0.19	+$0.07	-$0.19	N/A	N/A
5/13/2025	Q1 2025	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	8.33	8.33
CNTB Connect Biopharma	0.01	10.25	10.25
ERAS Erasca	N/A	12.35	12.35
RGNX REGENXBIO	N/A	2.93	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
CNTB Connect Biopharma	58.72%
ERAS Erasca	67.78%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	29.80%
CNTB Connect Biopharma	22.60%
ERAS Erasca	14.40%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
CNTB Connect Biopharma	110	55.56 million	43.00 million	Optionable
ERAS Erasca	120	283.29 million	242.49 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable

CNTB, RGNX, ERAS, and CMPX Headlines

Recent News About These Companies

REGENXBIO Publishes Preclinical Data Highlighting RGX-202’s Potential for Duchenne Muscular Dystrophy

August 1 at 4:48 AM | insidermonkey.com

GSA Capital Partners LLP Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX)

August 1 at 3:28 AM | marketbeat.com

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

July 31 at 7:05 AM | prnewswire.com

REGENXBIO (RGNX) Expected to Announce Quarterly Earnings on Thursday

July 31 at 3:19 AM | marketbeat.com

Cerity Partners LLC Makes New $228,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)

July 29, 2025 | marketbeat.com

Analysts Set REGENXBIO Inc. (NASDAQ:RGNX) Target Price at $31.63

July 28, 2025 | americanbankingnews.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Brokerages

July 25, 2025 | marketbeat.com

REGENXBIO Inc. (RGNX): A Bull Case Theory

July 24, 2025 | insidermonkey.com

FY2028 EPS Estimates for REGENXBIO Raised by Leerink Partnrs

July 21, 2025 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company

July 18, 2025 | finance.yahoo.com

REGENXBIO Announces Publication of Preclinical Results Demonstrating ...

July 11, 2025 | morningstar.comM

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

July 10, 2025 | prnewswire.com

RGNX | REGENXBIO Inc. Annual Income Statement - MarketWatch

July 6, 2025 | marketwatch.com

Janney Montgomery Scott LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)

July 4, 2025 | marketbeat.com

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts

June 9, 2025 | benzinga.com

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

June 6, 2025 | seekingalpha.com

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

June 6, 2025 | biopharmadive.comB

RegeNXBio shares fall, despite positive new data on RGX-202

June 6, 2025 | thepharmaletter.comT

Regenxbio’s Duchenne gene therapy data positive as shares falter

June 5, 2025 | bioworld.comB

Regenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene Therapy

June 5, 2025 | biospace.comB

REGENXBIO updates Phase 1/2 data for Duchenne candidate

June 5, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, RGNX, ERAS, and CMPX Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$2.95 -0.02 (-0.67%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.95 0.00 (0.00%)

As of 08/1/2025 07:22 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Connect Biopharma NASDAQ:CNTB

$2.00 -0.02 (-0.99%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.04 +0.04 (+2.00%)

As of 08/1/2025 04:20 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Erasca NASDAQ:ERAS

$1.39 -0.03 (-1.77%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.38 0.00 (-0.36%)

As of 08/1/2025 07:17 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

REGENXBIO NASDAQ:RGNX

$8.19 -0.32 (-3.76%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$8.20 +0.02 (+0.18%)

As of 08/1/2025 06:31 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time